Vogt–Koyanagi–Harada disease during chemoimmunotherapy for non‐small cell lung cancer
Abstract Vogt–Koyanagi–Harada disease (VKHD) is a rare systemic granulomatous autoimmune disease that affects melanocyte‐rich organs such as eye, inner ear, meninges, skin, and hair. VKHD leads to chronic uveal inflammation accompanied by a decline in visual acuity in some patients when appropriate...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-04-01
|
| Series: | Respirology Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/rcr2.545 |
| _version_ | 1811215024650190848 |
|---|---|
| author | Yuri Kurono Takayuki Takeda Yusuke Kunimatsu Nozomi Tani Izumi Hashimoto Kazuki Hirose |
| author_facet | Yuri Kurono Takayuki Takeda Yusuke Kunimatsu Nozomi Tani Izumi Hashimoto Kazuki Hirose |
| author_sort | Yuri Kurono |
| collection | DOAJ |
| description | Abstract Vogt–Koyanagi–Harada disease (VKHD) is a rare systemic granulomatous autoimmune disease that affects melanocyte‐rich organs such as eye, inner ear, meninges, skin, and hair. VKHD leads to chronic uveal inflammation accompanied by a decline in visual acuity in some patients when appropriate corticosteroid treatment was not initiated in an early phase. Immune checkpoint inhibitors (ICIs) are widely used in the treatment of several kinds of cancers and chemoimmunotherapy has become the standard of care in the first‐line treatment of non‐small cell lung cancer (NSCLC). While ICIs induce immune‐related adverse events, drug‐induced VKHD is quite rare with only four reports in the ICI monotherapy; three patients with melanoma and one patient with NSCLC. We describe the first case of VKHD during chemoimmunotherapy including pembrolizumab in a patient with NSCLC, which was successfully treated with corticosteroid without any sequela. |
| first_indexed | 2024-04-12T06:14:20Z |
| format | Article |
| id | doaj.art-e21da7961bb547eaa274e25cf3e73fe1 |
| institution | Directory Open Access Journal |
| issn | 2051-3380 |
| language | English |
| last_indexed | 2024-04-12T06:14:20Z |
| publishDate | 2020-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Respirology Case Reports |
| spelling | doaj.art-e21da7961bb547eaa274e25cf3e73fe12022-12-22T03:44:34ZengWileyRespirology Case Reports2051-33802020-04-0183n/an/a10.1002/rcr2.545Vogt–Koyanagi–Harada disease during chemoimmunotherapy for non‐small cell lung cancerYuri Kurono0Takayuki Takeda1Yusuke Kunimatsu2Nozomi Tani3Izumi Hashimoto4Kazuki Hirose5Department of Respiratory Medicine Japanese Red Cross Kyoto Daini Hospital Kyoto JapanDepartment of Respiratory Medicine Japanese Red Cross Kyoto Daini Hospital Kyoto JapanDepartment of Respiratory Medicine Japanese Red Cross Kyoto Daini Hospital Kyoto JapanDepartment of Respiratory Medicine Japanese Red Cross Kyoto Daini Hospital Kyoto JapanDepartment of Respiratory Medicine Japanese Red Cross Kyoto Daini Hospital Kyoto JapanDepartment of Respiratory Medicine Japanese Red Cross Kyoto Daini Hospital Kyoto JapanAbstract Vogt–Koyanagi–Harada disease (VKHD) is a rare systemic granulomatous autoimmune disease that affects melanocyte‐rich organs such as eye, inner ear, meninges, skin, and hair. VKHD leads to chronic uveal inflammation accompanied by a decline in visual acuity in some patients when appropriate corticosteroid treatment was not initiated in an early phase. Immune checkpoint inhibitors (ICIs) are widely used in the treatment of several kinds of cancers and chemoimmunotherapy has become the standard of care in the first‐line treatment of non‐small cell lung cancer (NSCLC). While ICIs induce immune‐related adverse events, drug‐induced VKHD is quite rare with only four reports in the ICI monotherapy; three patients with melanoma and one patient with NSCLC. We describe the first case of VKHD during chemoimmunotherapy including pembrolizumab in a patient with NSCLC, which was successfully treated with corticosteroid without any sequela.https://doi.org/10.1002/rcr2.545Chemoimmunotherapyimmune‐related adverse eventnon‐small cell lung cancerpembrolizumabVogt–Koyanagi‐Harada disease |
| spellingShingle | Yuri Kurono Takayuki Takeda Yusuke Kunimatsu Nozomi Tani Izumi Hashimoto Kazuki Hirose Vogt–Koyanagi–Harada disease during chemoimmunotherapy for non‐small cell lung cancer Respirology Case Reports Chemoimmunotherapy immune‐related adverse event non‐small cell lung cancer pembrolizumab Vogt–Koyanagi‐Harada disease |
| title | Vogt–Koyanagi–Harada disease during chemoimmunotherapy for non‐small cell lung cancer |
| title_full | Vogt–Koyanagi–Harada disease during chemoimmunotherapy for non‐small cell lung cancer |
| title_fullStr | Vogt–Koyanagi–Harada disease during chemoimmunotherapy for non‐small cell lung cancer |
| title_full_unstemmed | Vogt–Koyanagi–Harada disease during chemoimmunotherapy for non‐small cell lung cancer |
| title_short | Vogt–Koyanagi–Harada disease during chemoimmunotherapy for non‐small cell lung cancer |
| title_sort | vogt koyanagi harada disease during chemoimmunotherapy for non small cell lung cancer |
| topic | Chemoimmunotherapy immune‐related adverse event non‐small cell lung cancer pembrolizumab Vogt–Koyanagi‐Harada disease |
| url | https://doi.org/10.1002/rcr2.545 |
| work_keys_str_mv | AT yurikurono vogtkoyanagiharadadiseaseduringchemoimmunotherapyfornonsmallcelllungcancer AT takayukitakeda vogtkoyanagiharadadiseaseduringchemoimmunotherapyfornonsmallcelllungcancer AT yusukekunimatsu vogtkoyanagiharadadiseaseduringchemoimmunotherapyfornonsmallcelllungcancer AT nozomitani vogtkoyanagiharadadiseaseduringchemoimmunotherapyfornonsmallcelllungcancer AT izumihashimoto vogtkoyanagiharadadiseaseduringchemoimmunotherapyfornonsmallcelllungcancer AT kazukihirose vogtkoyanagiharadadiseaseduringchemoimmunotherapyfornonsmallcelllungcancer |